BrainEver SAS

Based in France, BrainEver SAS is a biotech firm dedicated to developing innovative therapies for neurodegenerative diseases, utilizing Homeoproteins to halt neuronal degeneration and improve patient outcomes. Founded in 2015 in Paris, France, BrainEver SAS is engaged in biotechnology focused on treating neurodegenerative conditions. The company has completed 2 deals and recently raised EUR 33. 000 mn in a Series B funding round led by investors including the European Innovation Council, Relyens, and iBionext, which represents the total amount raised to date.

The founder's prior ventures are not disclosed. BrainEver is focused on developing innovative therapies targeted at halting the progression of neurodegenerative diseases such as Amyotrophic Lateral Sclerosis (ALS), Parkinson's disease, and age-related retinal diseases. The company's core offerings are centered around the use of Homeoproteins, which are identified as specific factors for neuron maintenance and rejuvenation. These therapies aim to stop neuronal death while durably modifying the physiology and metabolism of surviving neurons, addressing significant unmet medical needs within the healthcare sector.

BrainEver's products are being developed for clinical use, with a specific focus on European markets, where there is a substantial demand for effective treatments for these debilitating conditions. The company’s clientele primarily includes healthcare providers and research institutions, as well as patients who are directly impacted by these neurodegenerative disorders. BrainEver's revenue model is built around partnerships and collaborations with various stakeholders in the biopharmaceutical industry, including academic institutions and healthcare organizations. The company anticipates generating revenue through grant funding, such as the recently awarded EUR 2.

5 mn from the European Innovation Council, which supports its research into Homeoproteins as novel therapies. Business transactions typically occur through collaborative agreements, where services are provided in exchange for funding or shared equity in the developed products. This model is particularly relevant as BrainEver progresses its drug candidates toward clinical trials and eventual market introduction. The company aims to establish a sustainable revenue stream by advancing its flagship products, which include its Homeoprotein-based therapies, into later stages of development and commercialization.

BrainEver SAS plans to leverage its recent EUR 33. 000 mn funding from the Series B round to enhance its product pipeline and expand into new European markets. The company is focused on developing new therapies targeting ALS and Parkinson's disease, with plans for clinical trial launches in the coming two years. The funding will be utilized to support research and development efforts, particularly in the advancement of its Homeoprotein-based products, aiming for commercialization within the next five years.